Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness Using “Manufacturing by Design” Methodology
Summary: Allogeneic T-cell therapies are moving toward late-stage clinical trials and commercial registration with the promise of having these breakthrough therapies available for market launch. As an outcome of these dynamic changes in the market, cell and gene therapy providers continue to make new investments to improve process manufacturability, as it is the key driver for the commercial success of cell therapies.